Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?

The 21-gene recurrence score assay has been validated as a predictive biomarker in early-stage HR+ and HER2-breast cancer. It is not indicated for use in HER2+ disease based on national guidelines. In this study, we assessed the value of 21-gene recurrence score (RS), or OncotypeDX (ODX), testing in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilani, Nadeem, Crowley, Fionnuala, Mohanna, Mohamed, Itani, Mira, Yaghi, Marita, Saravia, Diana, Jabbal, Iktej, Dominguez, Barbara, Liang, Hong, Nahleh, Zeina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493134/
https://www.ncbi.nlm.nih.gov/pubmed/36137495
http://dx.doi.org/10.1016/j.breast.2022.09.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493134/
https://www.ncbi.nlm.nih.gov/pubmed/36137495
http://dx.doi.org/10.1016/j.breast.2022.09.002

Ejemplares similares